Meeting
2022 ASCO Annual Meeting
Patient-reported outcomes from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Authors
Bruno Sangro
Liver Unit and HPB Oncology Area, Clínica Universidad de Navarra and CIBEREHD, Pamplona, Spain
Bruno Sangro , Peter R Galle , Robin Kate Kelley , Chaiyut Charoentum , Enrico N De Toni , Yuriy Ostapenko , Jeong Heo , Ann-Lii Cheng , Arndt Vogel , Michelle Marcovitz , Jayne Abraham , Nikunj Patel , Alejandra Negro , Ghassan K. Abou-Alfa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT03298451
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4074)
DOI
10.1200/JCO.2022.40.16_suppl.4074
Abstract #
4074
Poster Bd #
62
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Presence and impact of antidrug antibodies (ADAs) to tremelimumab (T) or durvalumab (D) in the phase 3 HIMALAYA study of unresectable hepatocellular carcinoma (uHCC).
First Author: Oxana V. Crysler
Poster
2023 ASCO Annual Meeting
Temporal patterns of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).
First Author: George Lau
Poster
2023 ASCO Gastrointestinal Cancers Symposium
An open-label, multi-center phase IIIb study of durvalumab and tremelimumab as first-line treatment in patients with unresectable hepatocellular carcinoma (TREMENDOUS study).
First Author: Jia Fan
First Author: Matt D. Galsky